Sample 100

Evaluation Instructions

Important: Models were tasked with extracting evidence from documents. Some outputs may be low quality and should be scored accordingly.

Your task: Compare the model-generated prediction (right panel) against the ground truth criteria (left panel).

Clean view: Shows formatted, readable text for easy comparison
Diff view: Highlights differences between ground truth and prediction
Raw view: Shows original unformatted text as it appears in the dataset

Evaluation scale (0-4):

0 = No match: Prediction is unrelated or contradicts the target criteria
1 = Poor match: Minimal overlap with ground truth, major errors or omissions
2 = Partial match: Some key elements captured, but notable gaps or inaccuracies
3 = Good match: Most elements correct, minor differences or formatting issues
4 = Excellent match: Essentially identical content, fully correct capture

Consider both content accuracy and completeness. Some predictions may be technically "correct" but incomplete or out of order.

Ground Truth

INCLUSION CRITERIA

1. On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (with the exception of pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year prior to screening visit 2.
2. A change in ART regimen ≥ 28 days prior to screening visit 2 for reasons other than virologic failure (VF) (eg, tolerability, simplification, drug-drug interaction profile) is allowed.
3. No clinically significant documented historical resistance to the current ART regimen with the exception of isolated nucleoside reverse transcriptase inhibitor mutations including M184V or ≤ 2 thymidine analog mutations (TAMs: M41L, D67N, K70R, L210W, T215Y, and/or K219Q).
4. Plasma human immunodeficiency virus-1 (HIV-1) ribonucleic acid (RNA) < 50 copies/mL at screening visit 2.
5. Documented plasma HIV-1 RNA < 50 copies/mL for ≥ 12 months preceding screening visit 2 (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
6. Virologic elevations of ≥ 50 copies/mL (transient detectable viremia or "blips") prior to screening are acceptable.
7. Proviral phenotypic sensitivity to both teropavimab and zinlirvimab at screening or from protocol GS-US-536-5816 within 24 months prior to screening.
8. Screening clusters of differentiation 4 (CD4)+ T-cell count ≥ 200 cells/μL at screening visit 2.

EXCLUSION CRITERIA

1. Comorbid condition requiring ongoing immunosuppression.
2. Evidence of hepatitis C virus (HCV) infection (prior infection cleared spontaneously or with treatment is acceptable)Evidence of current hepatitis B virus (HBV) infection regardless of HBV surface antigen status, at the screening visit 2.
3. History of opportunistic infection or illness indicative of Stage 3 HIV disease.
4. Note: Other protocol defined Inclusion/

EXCLUSION CRITERIA

1. may apply.

Prediction

Amended Eligibility Criteria (Version 17)

INCLUSION CRITERIA

1. On stable oral antiretroviral therapy (ART) consisting of no more than 2 drug classes (excluding pharmacologic boosters cobicistat or ritonavir) for ≥ 1 year prior to screening visit.
2. Change in ART regimen ≥ 28 days prior to screening visit for reasons other than virologic failure (VF) (e.g., tolerability, simplification, drug-drug interaction profile) is allowed.
3. No clinically significant documented historical resistance to the current ART regimen with the exception of isolated nucleoside reverse transcriptase inhibitor mutations including M184V or ≤ 2 thymidine analog mutations (TAMs: M41L, D67N, K70R, L210W, T215Y, and K219Q).
4. Documented plasma HIV-1 RNA < 50 copies/mL for ≥ 12 months preceding screening visit (or undetectable HIV-1 RNA level according to the local assay being used if the limit of detection is ≥ 50 copies/mL).
5. Documented plasma HIV-1 RNA < 50 copies/mL at screening visit 2.
6. Proviral phenotypic sensitivity to both teropavimab and zinlirvimab at screening or from protocol GS-US-536-5816 within 24 months prior to screening.
7. Screening CD4+ T-cell count ≥ 200 cells/μL at screening visit 2.
8. No evidence of hepatitis C virus (HCV) infection (prior infection cleared spontaneously or with treatment is acceptable).
9. No evidence of current hepatitis B virus (HBV) infection, regardless of HBV surface antigen status.
10. No history of opportunistic infection or illness indicative of Stage 3 HIV disease.
11. No evidence of comorbid condition requiring ongoing immunosuppression.

EXCLUSION CRITERIA

1. Evidence of hepatitis C virus (HCV) infection (prior infection cleared spontaneously or with treatment is acceptable).
2. Evidence of current hepatitis B virus (HBV) infection, regardless of HBV surface antigen status.
3. History of opportunistic infection or illness indicative of Stage 3 HIV disease.
4. Other protocol-defined Inclusion/

EXCLUSION CRITERIA

1. may apply.
2. Notably, the revised criteria incorporate the findings from the study protocol, including the demonstration of enhanced clearance of HIV-1-infected cells by broadly neutralizing antibodies in vivo, as well as the successful maintenance of viral suppression in virologically suppressed participants treated with a combination of GS-5423, GS-2872, and lenacapavir.